Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oscotec Plans US Trial For SYK Inhibitor Amid Failures By Others

This article was originally published in PharmAsia News

Executive Summary

South Korean drug developer Oscotec is planning to conduct early stage clinical trials in the US for its spleen tyrosine kinase inhibitor to treat rheumatoid arthritis. The company is betting that it will be able to license out the drug candidate, which is set to become a first-in-class therapy amid development failures by global competitors.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts